Evidence map›Paper›PMID 42324575›Full record

ArticleEye and vision (London, England)2026

Prediction of axial elongation in adults with high myopia: the Wenzhou High Myopia Cohort Study.

Yuan Wang, Xue Rui, Yue Sun, Yan Li, Shihao Ding, Zhilu Zhang, Jie Lu, Meixin Wu, Jia Qu, Xiangtian Zhou and 1 more

Abstract read
In one paragraph

Article in Eye and vision (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuan WangOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), State Key Laboratory of Eye Health, National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xue RuiOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), State Key Laboratory of Eye Health, National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yue SunOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), State Key Laboratory of Eye Health, National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yan LiOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), State Key Laboratory of Eye Health, National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Shihao DingOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), State Key Laboratory of Eye Health, National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Zhilu ZhangOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), State Key Laboratory of Eye Health, National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Jie LuOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), State Key Laboratory of Eye Health, National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Meixin WuOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), State Key Laboratory of Eye Health, National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Jia QuOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), State Key Laboratory of Eye Health, National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xiangtian ZhouOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), State Key Laboratory of Eye Health, National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China. zxt@mail.eye.ac.cn.
Hao WuOujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), State Key Laboratory of Eye Health, National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China. wuhao@eye.ac.cn.

Funding

National Natural Science Foundation of China 82388101National Natural Science Foundation of China 82571257National Natural Science Foundation of China U25A2091
6 · The paper itself

Abstract

backgroundIdentifying individuals at high risk of axial elongation is crucial for managing adults with high myopia, as further elongation substantially increases the risk of vision-threatening complications. This study aimed to identify the optimal predictors for axial elongation in this population.

methodsThis prospective cohort study enrolled 1025 eyes from 532 adults with high myopia (18-60 years). We evaluated the predictive performance of nine candidate variables for rapid axial elongation, defined as a 2-year axial elongation of at least 0.10 mm. Predictors were selected using bidirectional stepwise regression. Model discrimination was assessed using the area under the receiver operating characteristic curve (AUC), and the incremental value of the new model was quantified using integrated discrimination improvement (IDI).

resultsThe mean annual axial elongation rate was 0.020 ± 0.051 mm/year, and 24.78% of eyes developed rapid axial elongation. Stepwise regression constructed a full model (AUC = 0.811) including six predictors-age, sex, axial length, best-corrected visual acuity, choroidal thickness (ChT), and vascularity index. ChT showed the highest individual discriminative ability (AUC = 0.728), followed by age (AUC = 0.666). Removing age or ChT from the full model reduced the AUCs to 0.735 and 0.753, respectively (both P < 0.001), with IDIs of  - 0.116 and - 0.095 (both P < 0.001). In contrast, excluding sex only resulted in an IDI of - 0.008 (P = 0.032). Simplified models combining age and ChT, with or without sex, showed discrimination comparable to that of the full model, with only modest reductions in predictive performance (IDIs: -  0.028 and - 0.033, respectively; both P < 0.05). In the bivariate model, the predictive cut-off of ChT decreased progressively with age, ranging from 187 µm at age 20 to 29 µm at age 60. The results remained consistent in sensitivity analyses using alternative axial elongation definitions (0.05 mm and 0.15 mm). Nonlinear relationship analyses revealed that thinner choroids were associated with faster axial elongation rate only below an inflection point.

conclusionsChT and age are the optimal predictors for axial elongation in adults with high myopia. These findings establish their dominant role in personalized management and support further investigation into choroidal architecture to guide proactive, choroid-centered strategies.

trial registrationThis study was registered with the Chinese Clinical Trial Registry (ChiCTR2100047424).

Indexed as

AgeAxial elongationChoroidal thicknessHigh myopiaPredictors

Identifiers

PMID42324575
PMCPMC13285501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.